{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:59:50Z","timestamp":1770357590694,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T00:00:00Z","timestamp":1419465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12185-014-1722-8","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T06:40:39Z","timestamp":1419403239000},"page":"154-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A phase 1\/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia"],"prefix":"10.1007","volume":"101","author":[{"given":"Chiaki","family":"Nakaseko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,25]]},"reference":[{"key":"1722_CR1","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"1722_CR2","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"1722_CR3","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1200\/jco.2010.28.15_suppl.6509","volume":"28","author":"C Gambacorti-Passerini","year":"2010","unstructured":"Gambacorti-Passerini C, Cortes J, Khoury H, Baccarani M, Kantarjian H, Chandy M, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance\/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol. 2010;28:6509.","journal-title":"J Clin Oncol"},{"key":"1722_CR4","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood"},{"key":"1722_CR5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1078-0432.CCR-11-2378","volume":"18","author":"AI Daud","year":"2012","unstructured":"Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, et al. Phase I study of bosutinib, a src\/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012;18:1092\u2013100.","journal-title":"Clin Cancer Res"},{"key":"1722_CR6","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1200\/JCO.2009.26.5371","volume":"28","author":"C Gambacorti-Passerini","year":"2010","unstructured":"Gambacorti-Passerini C, Cortes JE, Khoury HJ, Baccarani M, Kantarjian H, Chandy M, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance\/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol. 2010;28:6509.","journal-title":"J Clin Oncol"},{"key":"1722_CR7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s12185-009-0260-2","volume":"89","author":"H Sakamaki","year":"2009","unstructured":"Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, et al. Phase 1\/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2009;89:332\u201341.","journal-title":"Int J Hematol"},{"key":"1722_CR8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","volume":"89","author":"A Tojo","year":"2009","unstructured":"Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+\u00a0CML or relapsed\/refractory Ph+\u00a0ALL. Int J Hematol. 2009;89:679\u201388.","journal-title":"Int J Hematol"},{"key":"1722_CR9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-012-1026-9","volume":"95","author":"K Usuki","year":"2012","unstructured":"Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, et al. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+\u00a0CML or relapsed\/refractory Ph+\u00a0ALL: a 36-month analysis of a phase I and II study. Int J Hematol. 2012;95:409\u201319.","journal-title":"Int J Hematol"},{"key":"1722_CR10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12185-011-0841-8","volume":"93","author":"H Nakamae","year":"2011","unstructured":"Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93:624\u201332","journal-title":"Int J Hematol."},{"key":"1722_CR11","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+\u00a0neoplastic cells. Cancer Res. 2006;66:11314\u201322.","journal-title":"Cancer Res"},{"key":"1722_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","volume":"66","author":"MM Schittenhelm","year":"2006","unstructured":"Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, et al. Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473\u201381.","journal-title":"Cancer Res"},{"key":"1722_CR13","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1124\/mol.105.020172","volume":"69","author":"Z Chen","year":"2006","unstructured":"Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69:1527\u201333.","journal-title":"Mol Pharmacol"},{"key":"1722_CR14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816\u00a0V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752\u20139.","journal-title":"Blood"},{"key":"1722_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23:477\u201385.","journal-title":"Leukemia"},{"key":"1722_CR16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/phar.1266","volume":"33","author":"E Irvine","year":"2013","unstructured":"Irvine E, Williams C. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Pharmacotherapy. 2013;33:868\u201381.","journal-title":"Pharmacotherapy"},{"key":"1722_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804:445\u201353.","journal-title":"Biochim Biophys Acta"},{"key":"1722_CR18","first-page":"1117","volume":"88","author":"F Cervantes","year":"2003","unstructured":"Cervantes F, Hernandez-Boluda JC, Steegmann JL, Conde E, Alvarez-Larran A, Lopez-Jimenez J, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica. 2003;88:1117\u201322.","journal-title":"Haematologica"},{"key":"1722_CR19","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143\u201350.","journal-title":"Blood"},{"key":"1722_CR20","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540\u20136.","journal-title":"Blood"},{"key":"1722_CR21","unstructured":"SPRYCEL\u00ae dasatinib Princeton. NJ: Bristol-Myers Squibb; 2014."},{"key":"1722_CR22","unstructured":"BOSULIF\u00ae bosutinib New York. NY: Pfizer Labs; 2013."},{"key":"1722_CR23","unstructured":"Tasigna\u00ae nilotinib East Hanover. NJ: Novartis Pharmaceuticals Corporation; 2014."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1722-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1722-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T23:58:49Z","timestamp":1566172729000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1722-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,25]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1722-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,25]]}}}